CT-G32
/ Celltrion
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 19, 2025
Celltrion steps into weight-loss market with oral rival to Wegovy, Mounjaro
(KED Global)
- "The company announced on Wednesday that it is developing CT-G32, an orally administered quadruple-receptor agonist designed to activate four metabolic pathways simultaneously, an approach that would move beyond the GLP-1 and dual-agonist injections, like Wegovy and Mounjaro, that dominate the global obesity drug market....Patent registrations have been completed, and formal preclinical development is planned for 2026."
New molecule • Patent • Preclinical • Obesity
1 to 1
Of
1
Go to page
1